Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
Surviving a Merger: HBA Takes a Look
Progress for women has always been on the agenda for the Healthcare Businesswomen}s Association. Founded in 1979, with almost 100 members, HBA is now more than 1,000 members strong. To support its commitment to the advancement of women in the healthcare industry, HBA has tracked key issues affecting women}s career development since 1997.
Advertisement
Articles in this issue
about 25 years ago
Overview of the Industry: A World of Opportunitiesabout 25 years ago
I Have A Dream: Communicating a Vision Helps Managers Become Leadersabout 25 years ago
On the Right Path: Sales Careers in PharmaAdvertisement
Related to this article
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.
Inizio's Elaine Ferguson on why connecting talent across 10,500 employees and four business units is fundamental to delivering client value.
Bristol Myers Squibb’s Wendy Short Bartie on recasting corporate affairs as an enterprise value engine that connects trust, access and the patient voice.
Cellectis is pivoting from allogeneic CAR-T development to become an in vivo gene editing company, discontinuing its lasme-cel and eti-cel programs.
Novo Nordisk rebrands as "Novo" under it's "Lasting health starts now" tagline, pairing both with a new cultural framework called "The Novo Way."
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
The Battle to Own the GLP-1 Patient Journey
3
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
4
Understanding the Latest with MFN Pricing and What It Means to Pharma
5